

Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene

NOBUHIKO KOJIMA*, JIAN WANG†, ISABELLE M. MANSUY†, SETH G. N. GRANT‡, MARK MAYFORD†, AND ERIC R. KANDEL†§

*Laboratory of Neurochemistry, National Institute for Physiological Sciences, Okazaki 444, Japan; †Center for Neurobiology and Behavior, College of Physicians and Surgeons of Columbia University, New York State Psychiatric Institute, and Howard Hughes Medical Institute, 722 West 168th Street, New York, NY 10032; and ‡Center for Genome Research and Center for Neuroscience, University of Edinburgh, West Mains Road, Edinburgh EH9 3JQ, United Kingdom

Contributed by Eric R. Kandel, February 28, 1997

ABSTRACT To examine the physiological role of the Fyn tyrosine kinase in neurons, we generated transgenic mice that expressed a *fyn* cDNA under the control of the calcium/calmodulin-dependent protein kinase II α promoter. With this promoter, we detected only low expression of Fyn in the neonatal brain. In contrast, there was strong expression of the *fyn*-transgene in neurons of the adult forebrain. To determine whether the impairment of long-term potentiation (LTP) observed in adult *fyn*-deficient mice was caused directly by the lack of Fyn in adult hippocampal neurons or indirectly by an impairment in neuronal development, we generated *fyn*-rescue mice by introducing the wild-type *fyn*-transgene into mice carrying a targeted deletion in the endogenous *fyn* gene. In *fyn*-rescue mice, Schaffer collateral LTP was restored, even though the morphological abnormalities characteristic of *fyn*-deficient mice were still present. These results suggest that Fyn contributes, at least in part, to the molecular mechanisms of LTP induction.

Fyn, one of the Src-related non-receptor tyrosine kinases, is highly expressed in the central nervous system and the immune system. A physiological role for Fyn in brain function was first suggested by the analysis of *fyn*-deficient mice generated by homologous recombination. These mice exhibited an impaired long-term potentiation (LTP), a long-lasting enhancement of synaptic transmission that is thought to be the cellular basis for learning and memory, as well as a spatial learning impairment (1). Interestingly, in contrast to Fyn, the disruption of other members of the Src family kinases does not cause any obvious neurological phenotypes (2) or any alteration in LTP (1). These results suggest that Fyn signaling may contribute to neuronal plasticity. However, the analysis of the phenotype in *fyn*-deficient mice was complicated by the presence of a number of other neurological defects, including uncoordinated hippocampal architecture, reduced neural cell adhesion molecule-dependent neurite outgrowth, and decreased susceptibility to kindling (1, 3, 4). In addition, some other lines of *fyn*-deficient mice expressing a *fyn*- β -galactosidase fusion protein showed abnormal suckling behavior, impaired myelination, increased fearfulness, and enhanced seizure susceptibility (5–8). The observed pleiotropic effect of the lack of Fyn suggests that, in the brain, Fyn might be involved in several signal transduction pathways in a variety of cell types and at different developmental stages.

To determine whether Fyn is directly involved in the signaling pathway required for LTP induction or if the phenotype observed is solely due to the malformation of the hippocam-

pus, we attempted to rescue Fyn expression in the *fyn*-deficient mice by expressing *fyn* cDNA on a *fyn*-deficient genetic background. For this purpose, we used the calcium/calmodulin-dependent protein kinase II α (CaMKII α) promoter so that the transgene is expressed postnatally only in the forebrain and in neurons and not in glial cells. LTP was normal in the hippocampus expressing transgenic Fyn, even though the morphological abnormalities were still present. These results suggest that impairment of LTP observed in adult *fyn*-deficient mice was caused directly by the lack of Fyn in adult hippocampal neurons, but not indirectly by an impairment in neuronal development.

MATERIALS AND METHODS

Generation of Fyn-Transgenic Mice. An *EcoRI*–*DraI* fragment of *fynB* cDNA (pmBF; ref. 9) was inserted into the *EcoRV* site of the vector, pNN265 (provided by N. Nakanishi, Harvard University), which was constructed by inserting a hybrid intron consisting of an adenovirus splice donor and an IgG splice acceptor (10) in 5' of the cloning site of the vector pCDNAI/Amp (Invitrogen) to give an efficient transgene expression. To add the CaMKII α promoter to this construct, *fynB* cDNA fragment with the 5' intron and simian virus 40 poly(A) signal sequences was excised using *NotI* and inserted into the pBluescript-based vector, pNN279 (provided by N. Nakanishi) into which the 8.5-kb fragment including the CaMKII α promoter (11) was inserted. The transgene was excised from the vector using *SalI*, and was then gel purified. Transgenic mice were generated by microinjecting the transgene into the pronuclei of fertilized eggs collected from C57BL6/CBA/F₁ mice; the injected eggs were then transferred into the oviduct of pseudopregnant females (12). Founders were screened by PCR of tail DNA using the transgene-specific primer pair. Mouse lines were established by crossing founders with the C57BL/6J \times 129Sv hybrid strain of hetero- or homozygous *fyn*-deficient mice (13). *Fyn*-rescue mice were obtained by breeding animals heterozygote for *fyn* gene with transgenic F₁ individuals.

Northern Blotting, Ribonuclease Protection Assay, and *in Situ* Hybridization. Total RNA was prepared from mouse forebrain using RNA isolation kit (Stratagene). For Northern blotting, 10 μ g of total RNA was loaded on a 1% denaturing formaldehyde agarose gel and transferred to a membrane (Duralose, Stratagene). The 252-bp fragment of 3' non-coding sequence (probe 2, shown in Fig. 1A) and *EcoRI*–*HindIII* fragment of *fynB* cDNA were labeled with ³²P and used as probes. For ribonuclease protection assay, a 617-bp fragment

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Copyright © 1997 by THE NATIONAL ACADEMY OF SCIENCES OF THE USA
0027-8424/97/944761-5\$2.00/0
PNAS is available online at <http://www.pnas.org>.

Abbreviations: CaMKII α , calcium/calmodulin-dependent protein kinase II α ; LTP, long-term potentiation; EPSP, excitatory postsynaptic potential; NMDA, *N*-methyl-D-aspartate; ACSF, artificial cerebrospinal fluid.

§To whom reprint requests should be addressed. e-mail: erk5@columbia.edu.

of 5' sequence of the transgene (probe 1, shown in Fig. 1A), including transgene specific 5' noncoding sequence and the part of *fynB* cDNA fragment, were subcloned into the vector, pGEM4Z (Promega). From the template DNA linearized at the *EcoRI* site, the antisense cRNA probe was synthesized using T7 RNA polymerase in the presence of [α - 32 P]UTP. Ribonuclease protection assay was performed using a commercially available kit (RPAII kit, Ambion, Austin, TX). Five micrograms of total RNA was hybridized with 0.3 ng cRNA probe (specific activity, 0.5×10^8 cpm/ μ g cRNA) at 45°C for 16–24 hr, and then digested with a mixture of RNase A and T1. The protected bands were separated on a 3.5% denaturing acrylamide gel and detected by autoradiography. The intensity of the bands was quantified by an imaging analyzer (BAS2000, FUJIX, Tokyo). For *in situ* hybridization, brains were quickly removed and frozen in dry ice. Sagittal sections (14 μ m thick) were prepared using a cryostat and mounted on glass slides coated with poly-L-lysine. Sections were dried at 50°C and kept at –80°C until used. The 252-bp fragment of transgene-specific 3' non-coding sequence (probe 2, shown in Fig. 1A) was inserted into the vector pGEM4Z (Promega). Antisense digoxigenin-labeled RNA probe was transcribed using digoxigenin-11-UTP (Boehringer Mannheim) and T7 RNA polymerase (Promega). Procedures for pretreatment of sections, hybridization, and detection were done according to Hashimoto and Obata (14).

Immunoblotting and *in Vitro* Immune-Complex Kinase Assay. The forebrains were homogenized in 10 vol of RIPA buffer (Tris·HCl, pH 7.5/1% Nonidet P-40/0.1% sodium deoxycholate/0.1% SDS/0.15 M NaCl/1 mM EDTA/1 mM sodium orthovanadate/10 μ g/ml aprotinin/10 μ g/ml leupeptin/1 mM phenylmethylsulfonyl fluoride), then centrifuged at $10,000 \times g$ for 10 min. Supernatants were rapidly frozen in liquid nitrogen and stored at –80°C until used. Protein concentration was determined using BCA protein assay kit (Pierce). For immunoblotting, the RIPA lysates were separated on 10% SDS/PAGE gel, transferred to nitrocellulose (Schleicher & Schuell), and probed with anti-Fyn (provided by M. Yasuda, National Institute of Physiological Science, Japan), anti-Src (mAB327, Oncogene Science), or anti-phosphotyrosine antibodies (PT66, Sigma). After incubation with horseradish peroxidase-conjugated anti-mouse IgG, signals were detected by chemiluminescence (ECL, Amersham). Quantification of signals was performed using an imaging analyzer (Quanti One, PDI Imaware Systems, Huntington Station, NY). For kinase assay, the RIPA lysate (200 μ g of protein) was immunoprecipitated with an anti-Fyn antibody conjugated with protein G–Sepharose (Pharmacia). Kinase reaction of the immunoprecipitants was started by adding 1 μ M [γ - 32 P]ATP (specific activity, 100 μ Ci/nmol; 1 Ci = 37 GBq) with 2.5 mg of acid-treated enolase (Sigma). After incubation at 25°C for 5 min, the reaction was stopped by boiling in the presence of SDS, and then separated on a SDS/10% polyacrylamide gel. The intensity of phosphorylated bands was quantified by an imaging analyzer (BAS2000, FUJIX).

Histological Staining. Anesthetized animals were perfused with 4% paraformaldehyde/0.5% picric acid in 0.1 M phosphate buffer (pH 7.4), and then their brains were removed and incubated in the same fixative at 4°C until used. Brains were sliced with a vibratome (Oxford) in 70- μ m-thick sections. Some sections were used for Nissl staining (cresyl violet) and some for immunohistochemistry. To visualize the fine dendritic structures, immunohistochemical staining was performed using anti-MAP2 monoclonal antibody (AP20, Leinco Technologies, St. Louis). After incubation with biotinylated anti-mouse IgG, the signal was detected using vectastain ABC kit (Vector Laboratories).

Electrophysiological Procedures. Brains were quickly removed and placed in an ice-cold (0°C to 4°C) artificial cerebrospinal fluid (ACSF) containing 124 mM NaCl/4.4 mM

KCl/25 mM NaHCO₃/1.0 mM Na₂HPO₄/2.0 mM CaCl₂/2.0 mM MgSO₄/10 mM glucose. Hippocampal slices (400 μ m thick) were transferred to an interface recording chamber containing cool ACSF (15–20°C). ACSF was perfused through the chamber (1–3 ml per min) as the temperature in the recording chamber was slowly increased to 30°C. Electrophysiological experiments were started after waiting at least 1 hr for the slices to recover. A fine bipolar stimulating electrode was used to stimulate Schaffer collateral fibers in the stratum radiatum of the CA1 region of the hippocampus. The stimulation strength was set to elicit responses equivalent to 25% of the maximum field excitatory postsynaptic potential (EPSP). Synaptic responses were elicited at 0.02 Hz and responses were recorded with low resistance (5–10 M Ω) glass microelectrodes filled with ACSF. Tetanus-induced LTP was elicited with trains (1 sec) of 100 Hz stimulation delivered twice with an interval of 20 sec.

RESULTS AND DISCUSSION

Transgenic Fyn Is Expressed at High Levels in the Neurons of Postnatal Forebrain Postnatally. A founder mouse carrying the *fyn*-transgene (Fig. 1A) was obtained. Northern blot analysis and *in situ* hybridization were performed to evaluate the level and pattern of transgene expression in the brain of F₁ offspring. Transgenic *fyn* mRNA of the expected size (\approx 4 kb) was detected in the forebrain of 1-month-old transgenic mice (Fig. 1B). This band was larger than the endogenous *fyn* mRNA (2.8 kb) due to an additional non-coding sequence derived from the transgene construct. Quantitative analysis showed that the level of transgenic *fyn* mRNA is approxi-




FIG. 1. Generation of *fyn*-transgenic mice and expression of *fyn*-transgene. (A) Schematic representation of the transgene construct that is composed of a 8.5-kb fragment, including the CaMKII α promoter, a hybrid intron consisting of an adenovirus splice donor, and an IgG splice acceptor, an *EcoRI*–*DraI* fragment of *fynB* cDNA, and a simian virus 40 poly(A) signal sequences. Transgenic mice were generated as described. The probes for detection of transgene mRNA and for ribonuclease protection assay are indicated with thick lines (probes 1 and 2, respectively). (B) Northern blot analysis on forebrain. Total RNA prepared from wild-type (wt) and transgenic littermates (Tg) was electrophoresed on formaldehyde agarose gel, transferred onto nylon membrane, and hybridized with probe 1 shown in A. Upper and *fynB* cDNA A Lower. (C) Detection of the transgene mRNA in brain sections. Sagittal brain sections prepared from wild-type (wt) and transgenic (Tg) littermates were hybridized with digoxigenin-labeled cRNA probe 2 shown in A. (D) Developmental change in the level of transgene mRNA. Ribonuclease protection assay was performed on 1-day-old (P₁ Tg), 10-day-old (P₁₀ Tg), 3-week-old (P₂₁ Tg) transgenic, adult wild-type (Adult wt), and adult *fyn*^{–/–} (Adult *fyn*^{–/–}) forebrains. The protected bands corresponding to endogenous *fyn* mRNA (*fyn*) and the transgene transcript (*fyn* Tg) are designated by arrows.

mately four times higher than the endogenous one. *In situ* hybridization on adult brain sections revealed that the regional distribution of transgenic *fyn* mRNA was similar to *CaMKII α* mRNA (15). Whereas *fyn* mRNA is broadly distributed in the brain (16, 17), the transgenic *fyn* transcript was localized to neurons and restricted to the forebrain, including the neocortex, hippocampus, striatum, and the amygdaloid nucleus (Fig. 1C). To quantify transgenic *fyn* mRNA during postnatal development, a ribonuclease protection assay was performed on *fyn*-transgenic mouse forebrains (Fig. 1D). The time course of the *fyn*-transgene expression was similar to that of *CaMKII α* (18, 19). A very weak signal was detected in newborn brain and the levels of transgene expression increased over a 3-week postnatal period.

We next generated mice carrying the *fyn*-transgene on the *fyn*-deficient genetic background by mating *fyn*-transgenic mice with *fyn*-deficient mice. We refer to these mice as *fyn*-rescue mice. We then determined in brain extracts of *fyn*-rescue mice the level of the Fyn protein, derived from the transgene, as well as the level of Fyn kinase activity. We detected by immunoblot analysis (Fig. 2A) a protein band identical to the endogenous Fyn in the forebrain of 3-month-old rescue mice. Quantitative immunoblotting revealed that the level of transgenic Fyn protein was approximately four times higher than in wild-type littermates. An *in vitro* immune complex kinase assay showed that the *fyn*-transgene product was catalytically active; it could phosphorylate itself as well as the substrate enolase (Fig. 2B). The specific activity of transgenic Fyn kinase, estimated by the intensity of the phosphorylated bands compared with the relative amount of Fyn protein, was equivalent to the activity of the endogenous Fyn. We next examined the effects of *fyn*-transgene expression on the level of tyrosine-phosphorylated proteins in the forebrain by immunoblotting using anti-phosphotyrosine antibody. In *fyn*-deficient mice, multiple proteins (approximately 180, 120, and 100 kDa) were significantly less phosphorylated, suggesting that they are preferentially phosphorylated by Fyn *in vivo* (Fig. 2C). In *fyn*-rescue mice, the phosphorylation of these proteins was restored to the levels in wild-type animals. In addition, we detected a 60-kDa protein identified as phosphorylated transgenic Fyn.

Morphological Abnormalities Are Present in *fyn*-Rescue Hippocampus. We then examined the anatomy of the hippocampus in *fyn*-rescue mice. As shown in Fig. 3A, we observed the abnormal cell arrangement characteristic of the




FIG. 2. Fyn protein, kinase activity, and tyrosine phosphorylation in the *fyn*-rescue mice. (A) The extracts prepared from forebrains of 2- to 3-month-old wild-type (wt), *fyn*⁻ and *fyn*-rescue (*fyn*-rescue) mice were separated on a SDS/10% polyacrylamide gel and blotted with an anti-Fyn antibody. The band corresponding to Fyn protein is designated by an arrow. (B) Proteins from the same extracts were immunoprecipitated with an anti-Fyn antibody conjugated with protein G-Sepharose. The precipitates were incubated with [γ -³²P]ATP in the presence of enolase, and then resolved on a SDS/10% polyacrylamide gel. Fyn and enolase are indicated by arrows. (C) Proteins from the same brain extracts were blotted with an anti-phosphotyrosine antibody, PT66. The arrowheads indicate the bands that show less phosphorylation in *fyn*-deficient mice.




FIG. 3. Hippocampal morphology in *fyn*-deficient and *fyn*-rescue mice. (A) Nissl staining of rostral and caudal coronal hippocampal sections of wild-type (wt), *fyn*-deficient (*fyn*⁻) and *fyn*-rescue (*fyn*-rescue) mice. Characteristic abnormal arrangements (arrowheads) of rostral dentate gyrus (DG) and caudal CA3 region in *fyn*-deficient mice were also observed in the rescue mice. (Bars = 500 μ m.) (B) Dendritic organization of the CA1 field in rescue mice. Apical dendrites of the pyramidal cells were revealed by immunohistochemical staining using anti-MAP2 antibody. CA1 pyramidal cell layer (pc) was less tightly packed and ectopic pyramidal cells (arrowheads) were frequently observed in *fyn*-deficient (*fyn*⁻) and *fyn*-rescue (*fyn*-rescue) mice. Dendrites ran across the stratum radiatum (sr) and lacunosum-moleculare (lm), but their lengths were shorter than in wild-type littermates. (Bar = 50 μ m.)

fyn-deficient mice. The caudal part of CA3 pyramidal cell layer was undulated (Fig. 3A, arrowheads) and the dorsal part of the dentate gyrus granular cell layer was occasionally perturbed in the rescue mice. To visualize the apical dendritic arborizations in CA1 pyramidal cells, immunohistochemical staining was performed using antibody to microtubule-associated protein MAP2 (Fig. 3B). As previously reported in the *fyn*-deficient mice, CA1 pyramidal cells were less tightly packed and ectopic pyramidal cells (Fig. 3B, arrowheads) were frequently observed in *fyn*-rescue mice. The dendritic regions were relatively narrow and the length of the apical dendrites were shortened in both *fyn*-deficient and *fyn*-rescue mice in comparison to

wild-type animals, although the dendritic arborization running across the stratum radiatum and lacunosum-moleculare was basically conserved in both mutant mice. These histological observations indicated that expression of the *fyn*-transgene, controlled by the *CaMKII α* promoter, did not rescue the morphological defects in the hippocampus of *fyn*-deficient mice. The undulation of hippocampal cell layers, commonly observed in the independent lines of *fyn*-deficient mice (1, 17) may reflect a failure in the regulation of cell number or in neuronal migration due to the lack of Fyn in neurons during development before the onset of the *CaMKII α* promoter driven expression of the *fyn*-transgene. Alternatively, the developmental phenotype may reflect the lack of Fyn in non-neuronal cells.

LTP Is Normal in *fyn*-Rescue Mice. To determine if synaptic plasticity was restored in the *fyn*-rescue mice despite their anatomical abnormality, we tested LTP in adult hippocampal slices comparable to those used in the initial studies of the *fyn*-deficient mice. As described previously (1), a tetanic stimulation evoking a postsynaptic response equivalent to 25% of the maximal EPSP was applied to hippocampal slices prepared from three groups of mice: wild-type, *fyn*-deficient, and *fyn*-rescue mice. We found that LTP was induced in wild-type and *fyn*-rescue slices, but not in *fyn*-deficient slices (Fig. 4A). The average value of relative EPSP slope 60 min after tetanic stimulation in *fyn*-rescue slices was significantly larger than in *fyn*-deficient slices ($135 \pm 7.2\%$ and $112.7 \pm 5.7\%$, respectively; $t = 2.39$, $P < 0.05$). In fact, the LTP in *fyn*-rescue slices was similar to that in wild-type slices ($148.3 \pm 8.7\%$; Fig. 4B). Thus, transgenic Fyn introduced into postnatal hippocampal neurons allowed us to distinguish between the morphological and the physiological defects in *fyn*-deficient mice. These results indicate that the impairment of LTP in *fyn*-deficient hippocampus is not caused by the developmental abnormality in the hippocampal architecture, but by the lack of Fyn in hippocampal neurons.

Age-Dependent Impairment of LTP in *fyn*-Deficient Mice. The *fyn*-deficient mice examined here and in the original studies were between 14 weeks and 6 months of age and showed a clear blunting of LTP (1). However, in the course of these experiments, we also examined younger *fyn*-deficient mice and found, surprisingly, that LTP was similar to that seen in wild-type animals (Fig. 4C). Thus, the LTP phenotype in the *fyn*-deficient mice is age dependent and appears only when the mice are over 10 weeks of age. This result further supports the idea that the LTP phenotype is not related to the developmental abnormality since young *fyn*-deficient mice show normal LTP, but also have a clearly disturbed hippocampal structure.

Compensatory Response of Src Is Also Age-Dependent. The mechanism of this age-dependent rescue of the adult Fyn phenotype is not known, but it could be mediated by developmentally regulated compensation by other kinases at younger ages (20, 21). Since we had earlier found that the Src kinase is elevated in the *fyn*-deficient mice (21), we now examined the developmental time course of this compensation. As shown in Fig. 4D, at all ages Src is expressed at higher levels in the *fyn*-deficient mice than in wild-type mice. However, at 14 weeks of age where the LTP deficit begins to be observed in the *fyn*-deficient mice, the level of compensatory Src expression is reduced, although *src*-deficient mice do not show any obvious neurological phenotype (2) and exhibited normal LTP (1), Src may be involved in the mechanisms of synaptic plasticity at least in the context of a Fyn deficiency. Also, LTP induced by pairing the synaptic input with strong postsynaptic depolarization of CA1 pyramidal cells in *fyn*-deficient mice is blocked by the tyrosine kinase inhibitor genistein, suggesting that other tyrosine kinases may contribute to LTP induction (T. J. O'Dell, unpublished results).




FIG. 4. LTP in *fyn*-rescue and young *fyn*-deficient mice and Src compensation in *fyn*-deficient mice. (A) Field EPSP recorded before and after tetanic stimulation in slices from adult wild-type (wt, ■), *fyn*-deficient (*fyn*⁻, △), and *fyn*-rescue mice (*fyn*-rescue, ▲). Each point is the mean \pm SEM of the field EPSP slope. Wild-type mice: $n = 8$ animals, 13 slices; *fyn*-deficient mice: $n = 9$ animals, 16 slices; *fyn*-rescue mice: $n = 11$ animals, 32 slices. (B) LTP measured 1 hr after tetanic stimulation. Wild-type (wt) mice: $148.3 \pm 8.7\%$ ($n = 8$); *fyn*-rescue (*fyn*-rescue) mice: $135.0 \pm 7.2\%$ ($n = 9$); *fyn*-deficient (*fyn*⁻) mice: $112.7 \pm 5.7\%$ ($n = 11$). Wild-type mice versus *fyn*-rescue mice: $t = 1.14$, not significant; *fyn*-rescue mice versus *fyn*-deficient mice: $t = 2.39$, $P < 0.05$. (C) Time course of LTP in wild-type (wt, ●) and *fyn*-deficient (*fyn*⁻, □) mice. Each point is the percentage of LTP obtained at different age. Wild-type mice: 2 weeks, $n = 5$; 6 weeks, $n = 6$; 10 weeks, $n = 6$; 14 weeks, $n = 9$. *fyn*-deficient mice: 2 weeks, $n = 12$; 6 weeks, $n = 7$; 10 weeks, $n = 4$; 14 weeks, $n = 6$. (D) Src levels in wild-type (wt) and *fyn*-deficient (*fyn*) mice of different postnatal ages. Protein extract from mice aged 2, 6, 10, 12, and 14 weeks. The levels of Src are indicated by the arrow.

How Does Fyn Contribute to the Mechanisms of LTP Induction? The findings that Fyn contributes directly to LTP raises the question: How does it produce its effects? As we have shown previously (1), the fact that strong stimulation could induce LTP in fyn-deficient mice suggests that Fyn is not essential for LTP induction, but may act as a modulatory molecule that influences the threshold for the induction of LTP. This effect might be mediated through tyrosine phosphorylation of other proteins required for LTP. What might these proteins be? One candidate is protein kinase C. In hematopoietic cells, Fyn is involved in phosphatidylinositol signal transduction pathway (22, 23). If Fyn also interacts with phospholipase C in neurons, the activity of protein kinase C required for LTP induction (24–26) might be altered in fyn-deficient mice. A second candidate is the *N*-methyl-D-aspartate (NMDA) receptor. Thus, tyrosine phosphorylation has also been shown to modulate the function of certain neurotransmitter-gated ion channels (27–29). In particular, the 2A and 2B subunits of the NMDA receptor are the targets of tyrosine phosphorylation (29–31), and indeed tyrosine phosphorylation of NMDA receptor 2B is increased after LTP induction (32, 33). The NMDA receptor may not be the only target for Fyn as NMDA receptor associated tyrosine phosphoproteins are also regulated by Fyn (S.G.N.G., unpublished results). The NMDA receptors 2A and 2B can actually be phosphorylated by Fyn *in vitro* (34) and these were shown to be hypophosphorylated in fyn-deficient mice (unpublished results). Finally, a third possibility is that Fyn might be involved in neural cell adhesion molecule signaling which is also required for normal LTP and spatial learning (35–37). In fact, neural cell adhesion molecule-dependent neurite outgrowth of fyn-deficient neurons is impaired in culture (3).

Taken together our data suggest that the Fyn signaling pathway is involved in the regulation of synaptic plasticity in a manner that is independent of its role in development. Consistent with an important role for Fyn in synaptic physiology, transgenic mice carrying a constitutively active form of Fyn in which the C-terminal negative regulatory tyrosine residue (Y531) was replaced by phenylalanine show enhanced seizure susceptibility and spontaneous death (N.K., unpublished results). In a larger sense, our experiments provide direct evidence that using the CaMKII α promoter and the fyn-transgene, it is possible to rescue LTP in animals whose gene has been knocked out by homologous recombination. Combined with region-specific and regulated (38) expression of transgenes, transgene rescue provides an additional method for evaluating the contribution of individual genes to synaptic plasticity and behavior.

We thank Harriet Ayers and Irma Trumpet for typing, Monica Mendelsohn for the generation of the transgenic mice, Dr. M. Osman for animal care, S. Yuasa and S. Furuya for technical advice for histological part of this study, R. M. Perlmutter for providing fynB cDNA pmBF, N. Nakanishi for pNN265 and pNN279, and M. Yasuda for anti-Fyn monoclonal antibody. This research was supported by the Howard Hughes Medical Institute and in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan. N.K. was supported by a long-term fellowship from the Ministry of Education, Science and Culture of Japan.

- Grant, S. G. N., O'Dell, T. J., Karl, K. A., Stein, P. L., Soriano, P. & Kandel, E. R. (1992) *Science* **258**, 1903–1910.
- Soriano, P., Montgomery, C., Gesk, R. & Bradley, A. (1991) *Cell* **64**, 693–702.
- Beggs, H. E., Soriano, P. & Maness, P. F. (1994) *J. Cell Biol.* **127**, 825–833.

- Cain, D. P., Grant, S. G. N., Saucier, D., Hargreaves, E. L. & Kandel, E. R. (1995) *Epilepsy Res.* **22**, 107–114.
- Yagi, T., Aizawa, S., Tokunaga, T., Shigetani, Y., Takeda, N. & Ikawa, Y. (1993) *Nature (London)* **366**, 742–745.
- Umemori, H., Sato, S., Yagi, T., Aizawa, S. & Yamamoto, T. (1994) *Nature (London)* **367**, 572–576.
- Miyakawa, T., Yagi, T., Watanabe, S. & Niki, H. (1994) *Mol. Brain Res.* **27**, 179–182.
- Miyakawa, T., Yagi, T., Taniguchi, M., Matsuura, H., Tateishi, K. & Niki, H. (1995) *Mol. Brain Res.* **28**, 349–352.
- Cooke, M. P. & Perlmutter, R. M. (1989) *New Biol.* **1**, 66–74.
- Choi, T., Huang, M., Gorman, C. & Jaenisch, R. (1991) *Mol. Cell Biol.* **11**, 3070–3074.
- Mayford, M., Wang, J., Kandel, E. R. & O'Dell, T. J. (1995) *Cell* **81**, 891–904.
- Hogan, B., Costantini, F. & Lacy, E. (1986) *Manipulating the Mouse Embryo: A Laboratory Manual* (Cold Spring Harbor Lab. Press, Plainview, NY), pp. 90–182.
- Stein, P. L., Lee H.-M., Rich, S. & Soriano, P. (1992) *Cell* **70**, 741–750.
- Hashimoto, T. & Obata, K. (1991) *Neurosci. Res.* **12**, 514–527.
- Burgin, K. E., Waxham, M. N., Rickling, S., Westgate, S. A., Mobley, W. C. & Kelly, P. T. (1990) *J. Neurosci.* **10**, 1788–1798.
- Umemori, H., Wanaka, A., Kato, H., Takeuchi, M., Tohyama, M. & Yamamoto, T. (1992) *Mol. Brain Res.* **16**, 303–310.
- Yagi, T., Shigetani, Y., Okado, N., Tokunaga, T., Ikawa, Y. & Aizawa, S. (1993) *Oncogene* **8**, 3343–3351.
- Beaman-Hall, C. M., Hozza, M. J. & Vallano, M. L. (1992) *J. Neurochem.* **58**, 1259–1267.
- Sugiura, H. & Yamauchi, T. (1992) *Brain Res.* **593**, 97–104.
- Stein, P. L., Vogel, H. & Soriano, P. (1994) *Genes Dev.* **8**, 1999–2007.
- Grant, S. G. N., Karl, K. A., Kiebler, M. A. & Kandel, E. R. (1995) *Genes Dev.* **9**, 1909–1921.
- Shiroo, M., Goff, L., Biffen, M., Shivnan, E. & Alexander, D. (1992) *EMBO J.* **11**, 4887–4897.
- Karnitz, L. M., Sutor, S. L. & Abraham, R. T. (1994) *J. Exp. Med.* **179**, 1799–1808.
- Malinow, R., Schulman, H. & Tsien, R. W. (1989) *Science* **245**, 862–866.
- Wang, J. H. & Feng, D. P. (1992) *Proc. Natl. Acad. Sci. USA* **89**, 2576–2580.
- Abeliovich, A., Chen, C., Goda, Y., Silva, A. J., Stevens, C. F. & Tonegawa, S. (1993) *Cell* **75**, 1253–1262.
- Moss, S. J., Gorrie, G. H., Amato, A. & Smart, T. G. (1995) *Nature (London)* **377**, 344–348.
- Valenzuela, C. F., Machu, T. K., McKernan, R. M., Whiting, P., VanRenterghem, B. B., McManaman, J. L., Brozowski, S. J., Smith, G. B., Olsen, R. W. & Harris, R. A. (1995) *Mol. Brain Res.* **31**, 165–172.
- Moon, I. S., Apperson, M. L. & Kennedy M. B. (1994) *Proc. Natl. Acad. Sci. USA* **91**, 3954–3958.
- Wang, Y. T., Yu, X. M. & Salter, M. W. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 1721–1725.
- Chen, C. & Leonard, J. P. (1996) *J. Neurochem.* **67**, 194–200.
- Rastas, J. A. P., Brent, V. A., Voss, K., Errington, M. L., Bliss, T. V. P. & Gard, J. W. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 10452–10456.
- Rosenblum, K., Dudai, Y. & Richter-Levin, G. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 10457–10460.
- Suzuki, T. & Okumura-Noji, K. (1995) *Biochem. Biophys. Res. Commun.* **216**, 582–588.
- Lüthi, A. L., Laurent, J.-P., Figueroa, A., Müller, D. & Schachner, M. (1994) *Nature (London)* **372**, 777–779.
- Müller, D., Wang, C., Skibo, G., Toni, N., Cremer, H., Calaora, V., Rougon, G. & Kiss, J. Z. (1996) *Neuron* **17**, 413–422.
- Cremer, H., Lange, R., Christoph, A., Plomanm, M., Vopper, G., Roes, J., Brown, R., Baldwin, S., Kraemer, P., Scheff, S., Barthels, D., Rajewsky, K. & Wille, W. (1994) *Nature (London)* **367**, 455–457.
- Mayford, M., Bach, M. E., Huang, Y.-Y., Wang, L., Hawkins, R. D. & Kandel, E. R. (1996) *Science* **274**, 1678–1683.